Edinburgh Zoo sun bear, Babu, in remission after 'terminal cancer' diagnosis
Edinburgh Zoo has revealed a sun bear is in remission after they were dealt a terminal cancer diagnosis.
Babu, a 13-year-old bear, diagnosed with lymphoma in April 2024 after zookeepers noticed swelling in the lymph nodes across her body.
Her behaviour and eating habits also changed during this time, raising alarm. Following an investigation by the wildlife conservation charity's vets, Babu was diagnosed with lymphoma, the Daily Record reports.
READ MORE: Dubai-based gangland boss waging war in Edinburgh 'unmasked as ex football ultra'
READ MORE: Edinburgh yobs soak members of the public as cruel American trend makes its way over
This is a variety of cancer with very limited precedent in bears. After receiving a second opinion from veterinary oncologist Dr Isabel Miguel, a terminal diagnosis was confirmed.
As a result, the veterinary team at Edinburgh Zoo began to prioritise ensuring quality of life. At the time, it was believed that Babu had mere weeks or months to live.
The Royal Zoological Society of Scotland communicated the diagnosis to adopters and its members.
Sign up for Edinburgh Live newsletters for more headlines straight to your inbox
Veterinary surgeon at the Royal Zoological Society of Scotland Stephanie Mota commented: "This diagnosis was new territory. We found one similar case involving a Himalayan black bear in China, but it died suddenly and there was very little information available to guide us.
"Our top priority was that Babu was comfortable and happy in her last days."
According to the Royal Zoological Society of Scotland, bears are known to mask symptoms and it is therefore difficult to catch illnesses early. This was the case when Edinburgh Zoo's 20-year-old sun bear Rotana was put to sleep in October 2023 following a rapid spread of cancer.
The team carefully reviewed all available literature to help Babu, including studies on canine medicine as lymphoma is relatively common in dogs. They chose a treatment course that minimised potential side effects alongside pain relief, with the aim of slowing Babu's cancer and easing her discomfort.
However, to the surprise of staff, the sun bear's condition began to improve. Following six months of treatment, tests in October 2024 revealed a reduction in cancerous cells.
Further monitoring and additional tests carried out earlier this year showed no detectable signs of the disease. Dr Miguel also confirmed that Babu was in remission.
Head of veterinary services at RZSS Professor Simon Girling stated: "We're delighted that Babu has responded so positively to the medication, especially as we were in uncharted territory. With confirmation of remission, we've been able to stop her pain medication, and are now gradually reducing her cancer treatment while closely monitoring her condition."
Babu's weight is currently being recorded weekly, with daily behaviours and appetite also being monitored by keepers. An objective charting system is being employed to ensure any changes are spotted early.
Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages.
The animal's medication is being hidden in honey, which is her favourite food. Honey is normally reserved for special occasions, but has become part of Babu's twice-daily routine during her recovery.
Mota added: "She's really interested in digging around in her habitat for insects at the moment. These inquisitive, natural behaviours are really good signs that she is feeling happy and healthy."
Babu is among the most popular residents at Edinburgh Zoo, and her recovery has been met with joy. However, the veterinary team remain cautiously optimistic.
Dr Girling continued: "This news is better than we ever hoped for, but it wasn't what we expected and there's always a possibility that the cancer could return. For now, what matters most is that Babu is happy, healthy and back to her old self."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
USA Today
an hour ago
- USA Today
My 5-year-old survived cancer – twice. Don't put politics before medical research.
My 5-year-old survived cancer – twice. Don't put politics before medical research. | Opinion When you're watching your child battle cancer, every advancement matters. We can't afford to let misinformation and polarized politics dictate the future of lifesaving research. Show Caption Hide Caption Cuts to health research could impact clinical studies and trials at the NIH The Trump administration wants to cut health spending in the coming year, and plans to cut the budget at the National Institutes of Health by $18 billion. Few issues in American politics have consistently united both parties like the fight against cancer. While funding levels and strategies may differ, Democrats and Republicans alike recognize that cancer doesn't discriminate – and neither should our commitment to defeat it. Under the Biden administration, the Cancer Moonshot was relaunched to accelerate progress toward a cure. More recently, President Donald Trump announced his 'Stargate' initiative, which aims to harness artificial intelligence in detecting and treating cancer, including through personalized mRNA vaccines. In the United States, cancer is the leading cause of death by disease for children after infancy. Across the political spectrum, there remains a shared hope: that no one should have to endure the pain of losing a loved one or fight this deadly disease. Yet today, that consensus is showing signs of strain. State legislatures across the country are advancing bills to ban or severely restrict the use of – and further research into – breakthrough technologies like mRNA, a technology that is driving promising advancements in cancer. What should be a story of American scientific innovation is being twisted into a political talking point. And it's putting lives at risk. Opinion: Biden's diagnosis shows two things. Cancer hits everyone and some forgot that. My daughter survived cancer twice. Politicians can't imagine what we went through. If the politicians pushing these bans spent even a few minutes inside a pediatric oncology unit, maybe they'd understand. They'd see floors filled with sick children on small bicycles, pulling IV poles behind them. Children in hospital beds, brave beyond measure. And parents clinging to hope. I've seen it firsthand. I'm a mother whose 5-year-old daughter has survived cancer – twice. My daughter Charlie is one of a small percentage of pediatric cancer patients whose tumors don't show up on standard blood tests. Her cancer went undetected for more than a year. By the time doctors found it, it had already spread to her liver. She was just 3 years old and had Stage 4 cancer. Once Charlie's cancer was detected, we rushed into treatment: high-dose chemotherapy, stem cell transplants and multiple surgeries. After months of treatment, we got the news every parent prays for: Charlie was cancer-free. But just a few months later, scans revealed a relapse. Two small nodules were found on her lung. Her baby brother was only two months old when we learned her cancer had returned. Relapse treatment was grueling. Charlie lost weight and muscle mass. She needed a feeding tube to stay nourished, hydrated and medicated. But through it all, she never lost her smile. Her strength became ours. And while we juggled caring for a newborn and two other children, we held onto hope, because science gave us a reason to. Thanks to expert care at Seattle Children's and research-backed protocols, she's once again cancer-free. She started preschool this year. She's coloring, laughing and chasing her siblings again. Public funding for research saved my daughter's life Every option we had was made possible by decades of public investment in research. Families who came before us joined clinical trials. Lawmakers chose to fund pediatric science and cancer research. That is the same kind of work mRNA research builds on today. Researchers are developing an mRNA-based diagnostic test that could catch cancers like hers earlier, when they're more treatable. The test uses mRNA from her original tumor to detect any circulating cancer cells through a simple blood draw. Catching a relapse early could be lifesaving. We first learned about this test in 2023, and knowing it's almost within reach brings us, and families like ours, so much hope. Beyond mRNA-based diagnostic tests, mRNA has also shown early promise as a therapy for cancer patients, enabling personalized treatment that could more effectively target one's tumor. That kind of innovation is exactly what's under threat right now. The role of mRNA technology in oncology has been studied for decades, and yet some lawmakers want to roll this progress back, arguing it is untested and unsafe. This technology, along with many innovations that come from federally supported medical research, is a critical source of hope for families around the world. I'm a doctor. So is my mother. When she got cancer, I realized how little that mattered. | Opinion When you're watching your child battle cancer, every advancement matters. I know firsthand how critical it is to catch cancer early and have access to every possible treatment option. When politicians politicize science – when they ban or restrict it based on misinformation and politics – they aren't protecting families like mine. They're limiting our options. They're slowing down the breakthroughs that could save lives. We can't afford to let misinformation and polarized politics dictate the future of lifesaving research. Thanks to innovation in medical research, Charlie is thriving today, but far too many kids are still fighting. Let's ensure science continues to move forward for all of our children. Emily Stenson is a childhood cancer advocate and the mother of 5-year-old two-time cancer survivor Charlie Stenson. She lives in Seattle.
Yahoo
2 hours ago
- Yahoo
New test could transform diagnosis and treatment of STIs
A new rapid test for sexually transmitted infections could soon transform on-the-spot diagnosis and treatment. Birmingham-based Linear Diagnostics has secured £1 million in funding to develop the technology, which could deliver results in less than 20 minutes. The funding comes from the NIHR Invention for Innovation programme and will support a three-year project to finalise the test and prepare it for clinical trials. Dr Jean-Louis Duprey, head of research and development at Linear Diagnostics, said: "We are developing a near patient device that will overcome this conundrum." The company is working with the NIHR HealthTech Research Centre and the North East Innovation Lab to deliver the project. Dr Jana Suklan, senior methodologist at the HRC, said: "The NIHR HRC in Diagnostic and Technology Evaluation is delighted to be collaborating with the North East Innovation Lab to support Linear Diagnostics with their exciting technology. "Our research involves analysing unmet needs, examining current practice and identifying the most promising point in the patient pathway for implementing the technology." The test uses Linear's Exponential Amplification (EXPAR) technology, which detects bacterial DNA within minutes. The company has focused on STIs such as Neisseria gonorrhoeae and Chlamydia trachomatis, where rapid diagnosis is essential to prevent further transmission and begin treatment immediately.
Yahoo
10 hours ago
- Yahoo
SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy
VANCOUVER, British Columbia & TOKYO & WALTHAM, Mass., June 08, 2025--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to accelerating treatments for facioscapulohumeral muscular dystrophy (FSHD), and Modalis Therapeutics Corporation (TSE 4883; "Modalis"), a CRISPR-based epigenome editing therapeutics company focused on rare genetic diseases, today announced a strategic collaboration to develop an innovative therapy for FSHD, a debilitating muscular disorder affecting approximately 1 million individuals worldwide. The novel therapy leverages Modalis's proprietary CRISPR-GNDM® (Guide Nucleotide-Directed Modulation) technology, which can dynamically modulate gene expression without introducing double-strand DNA breaks. SOLVE FSHD will provide strategic funding to support the development of Modalis's MDL-103 program. MDL-103 is an innovative therapeutic solution that continuously suppresses the expression of the DUX4 gene, the toxic disease-causing gene for FSHD, which becomes abnormally activated due to epigenetic changes in the D4Z4 repeat region on chromosome 4. MDL-103 is designed to have durable activity over long periods of time under the control of a strong, muscle-specific promoter, and is delivered to the muscles of patients using a muscle-tropic AAV delivery system. Modalis's CRISPR-GNDM® technology has the potential to transform the treatment of FSHD by epigenetically silencing the expression of DUX4. "SOLVE FSHD is pleased to partner with Modalis and to add them to our diverse portfolio of collaborators that are advancing potential therapies for FSHD," stated Eva Chin, Executive Director of SOLVE FSHD. "SOLVE FSHD identified Modalis as a company committed to finding a cure for this debilitating condition. We were impressed by their unique approach to targeting the epigenetic cause of FSHD, using a platform technology that has shown promise in other neuromuscular diseases. We believe that the support from SOLVE FSHD will allow Modalis to accelerate the advancement of MDL-103 into clinical trials." "We are delighted to be working in partnership with SOLVE FSHD and greatly appreciate the invaluable support for the development of MDL-103," said Haru Morita, CEO of Modalis. "This strategic collaboration is a strong validation of Modalis's CRISPR-GNDM® technology and our MDL-103 program. As a pioneer in this technology, we have demonstrated promising long-term drug efficacy in mouse models, shown durable target engagement and safety in non-human primates, and exhibited excellent biodistribution in neuromuscular disorders. We believe that MDL-103, which incorporates CRISPR-GNDM® technology with a muscle tropic AAV delivery system, has significant potential as a breakthrough treatment for FSHD." About SOLVE FSHD SOLVE FSHD is a venture philanthropic organization established to catalyze innovation and accelerate key research in finding a cure for FSHD. Established by renowned Canadian entrepreneur and philanthropist, Chip Wilson, the Wilson family has committed $100 million to kick-start funding into projects that support the organizations' mission to solve FSHD by 2027. The goal of SOLVE FSHD is to find a solution that can slow down or stop muscle degeneration, increase muscle regeneration and strength, and improve the quality of life for those living with FSHD, visit About Modalis Therapeutics Corporation Modalis was founded in 2016 and conducts research and development activities in Massachusetts, USA. Modalis is a pioneering leader in the field of epigenetic medicine. Modalis develops therapeutics for patients suffering from serious genetic disorders such as neuromuscular diseases, CNS diseases, and cardiomyopathies. Modalis's proprietary CRISPR-GNDM® technology is capable of specifically up or down modulating the expression of disease-relevant genes without introducing double-strand DNA breaks. For more information, visit View source version on Contacts SOLVE FSHDAlexandra Grant, House of Wilsonalexandrag@ Modalis Therapeutics CorporationCorporate Planning Departmentmedia@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
